As of 2025-11-13, the Intrinsic Value of Renalytix AI PLC (RENX.L) is (1,607.30) GBP. This RENX.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 6.85 GBP, the upside of Renalytix AI PLC is -23,564.20%.
The range of the Intrinsic Value is (7,304.31) - (917.93) GBP
Based on its market price of 6.85 GBP and our intrinsic valuation, Renalytix AI PLC (RENX.L) is overvalued by 23,564.20%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (7,304.31) - (917.93) | (1,607.30) | -23564.2% |
| DCF (Growth 10y) | (1,998.74) - (15,794.71) | (3,491.81) | -51075.3% |
| DCF (EBITDA 5y) | (375.81) - (556.50) | (937.85) | -123450.0% |
| DCF (EBITDA 10y) | (934.23) - (1,395.83) | (937.85) | -123450.0% |
| Fair Value | -26.21 - -26.21 | -26.21 | -482.63% |
| P/E | (133.46) - (168.06) | (155.16) | -2365.2% |
| EV/EBITDA | (18.30) - (27.74) | (23.65) | -445.3% |
| EPV | (59.44) - (78.52) | (68.98) | -1107.0% |
| DDM - Stable | (75.75) - (689.56) | (382.65) | -5686.2% |
| DDM - Multi | (732.18) - (5,211.38) | (1,286.68) | -18883.7% |
| Market Cap (mil) | 34.54 |
| Beta | -0.63 |
| Outstanding shares (mil) | 5.04 |
| Enterprise Value (mil) | 37.47 |
| Market risk premium | 5.98% |
| Cost of Equity | 6.76% |
| Cost of Debt | 5.00% |
| WACC | 6.42% |